BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24511010)

  • 1. 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging of thymidine kinase 1 activity after 5-fluorouracil treatment in a mouse tumor model.
    Hong IK; Kim SY; Chung JH; Lee SJ; Oh SJ; Lee SJ; Oh J; Ryu JS; Kim TW; Kim DY; Moon DH
    Anticancer Res; 2014 Feb; 34(2):759-66. PubMed ID: 24511010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3'-deoxy-3'-[18F]fluorothymidine flare.
    Lee SJ; Kim SY; Chung JH; Oh SJ; Ryu JS; Hong YS; Kim TW; Moon DH
    Biochem Pharmacol; 2010 Nov; 80(10):1528-36. PubMed ID: 20723540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
    Lee HJ; Oh SJ; Lee EJ; Chung JH; Kim Y; Ryu JS; Kim SY; Lee SJ; Moon DH; Kim TW
    Cancer Chemother Pharmacol; 2015 May; 75(5):1005-13. PubMed ID: 25776904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
    Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
    Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
    Leyton J; Alao JP; Da Costa M; Stavropoulou AV; Latigo JR; Perumal M; Pillai R; He Q; Atadja P; Lam EW; Workman P; Vigushin DM; Aboagye EO
    Cancer Res; 2006 Aug; 66(15):7621-9. PubMed ID: 16885362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [
    Kim SY; Jung JH; Lee HJ; Soh H; Lee SJ; Oh SJ; Chae SY; Lee JH; Lee SJ; Hong YS; Kim TW; Moon DH
    Cancer Res; 2017 Dec; 77(24):7120-7130. PubMed ID: 29055019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of [
    Rapic S; Vangestel C; Verhaeghe J; Thomae D; Pauwels P; Van den Wyngaert T; Staelens S; Stroobants S
    Mol Imaging Biol; 2017 Feb; 19(1):109-119. PubMed ID: 27324368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of (18)F-FLT PET studies in lung tumors.
    Brockenbrough JS; Souquet T; Morihara JK; Stern JE; Hawes SE; Rasey JS; Leblond A; Wiens LW; Feng Q; Grierson J; Vesselle H
    J Nucl Med; 2011 Aug; 52(8):1181-8. PubMed ID: 21764789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylation status of thymidine kinase 1 following antiproliferative drug treatment mediates 3'-deoxy-3'-[18F]-fluorothymidine cellular retention.
    Sala R; Nguyen QD; Patel CB; Mann D; Steinke JH; Vilar R; Aboagye EO
    PLoS One; 2014; 9(7):e101366. PubMed ID: 25003822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model.
    Paproski RJ; Wuest M; Jans HS; Graham K; Gati WP; McQuarrie S; McEwan A; Mercer J; Young JD; Cass CE
    J Nucl Med; 2010 Sep; 51(9):1447-55. PubMed ID: 20720035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
    Moroz MA; Kochetkov T; Cai S; Wu J; Shamis M; Nair J; de Stanchina E; Serganova I; Schwartz GK; Banerjee D; Bertino JR; Blasberg RG
    Clin Cancer Res; 2011 Mar; 17(5):1099-110. PubMed ID: 21245090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic modeling of 3'-deoxy-3'-18F-fluorothymidine for quantitative cell proliferation imaging in subcutaneous tumor models in mice.
    Kim SJ; Lee JS; Im KC; Kim SY; Park SA; Lee SJ; Oh SJ; Lee DS; Moon DH
    J Nucl Med; 2008 Dec; 49(12):2057-66. PubMed ID: 18997037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.
    Frings V; van der Veldt AA; Boellaard R; Herder GJ; Giovannetti E; Honeywell R; Peters GJ; Thunnissen E; Hoekstra OS; Smit EF
    PLoS One; 2013; 8(5):e63705. PubMed ID: 23717468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging.
    Chen X; Yang Y; Berger I; Khalid U; Patel A; Cai J; Farwell MD; Langer C; Aggarwal C; Albelda SM; Katz SI
    Oncotarget; 2017 Apr; 8(15):24213-24223. PubMed ID: 27655645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxygen breathing affects 3'-deoxy-3'-18F-fluorothymidine uptake in mouse models of arthritis and cancer.
    Fuchs K; Kukuk D; Reischl G; Föller M; Eichner M; Reutershan J; Lang F; Röcken M; Pichler BJ; Kneilling M
    J Nucl Med; 2012 May; 53(5):823-30. PubMed ID: 22492733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproducibility of the kinetic analysis of 3'-deoxy-3'-[(18)F]fluorothymidine positron emission tomography in mouse tumor models.
    Choi SJ; Kim SY; Kim SJ; Lee JS; Lee SJ; Park SA; Lee SJ; Yun SC; Im KC; Oh SJ; Kim SW; Kim JS; Ryu JS; Moon DH
    Nucl Med Biol; 2009 Oct; 36(7):711-9. PubMed ID: 19720283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.
    Bradbury MS; Hambardzumyan D; Zanzonico PB; Schwartz J; Cai S; Burnazi EM; Longo V; Larson SM; Holland EC
    J Nucl Med; 2008 Mar; 49(3):422-9. PubMed ID: 18287265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
    Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
    J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels.
    Barthel H; Perumal M; Latigo J; He Q; Brady F; Luthra SK; Price PM; Aboagye EO
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):257-63. PubMed ID: 15791434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography.
    Kenny LM; Contractor KB; Stebbing J; Al-Nahhas A; Palmieri C; Shousha S; Coombes RC; Aboagye EO
    Clin Cancer Res; 2009 Nov; 15(21):6649-57. PubMed ID: 19861447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.